100+ Locations and Growing: A Milestone for FebriDx® Adoption
3 June 2026
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States, marking a meaningful milestone in its adoption for respiratory infection management. This growing footprint spans urgent care, primary care, concierge medicine, and collegiate health settings, underscoring increasing demand for diagnostic tools that deliver actionable insights at the point of care.
As respiratory testing remains inherently seasonal, current efforts are focused on supporting newly onboarded sites through evaluation, implementation, and early use of FebriDx® ahead of the upcoming respiratory season later this year. This includes integrating the test into clinical workflows, establishing ordering patterns, and enabling claims submission to third-party payers—key steps in demonstrating clinical utility, operational efficiency, and the underlying economic value proposition in real-world settings.
The expansion reflects a broader shift toward equipping clinicians with rapid, evidence-based information during the initial patient visit—supporting more confident treatment decisions, reducing diagnostic uncertainty, and reinforcing antimicrobial stewardship efforts. It also enhances patient engagement by enabling more informed discussions around care pathways.
Recent additions, including WellStreet Urgent Care, further highlight the accelerating momentum behind rapid diagnostic solutions that integrate seamlessly into outpatient workflows and support frontline providers.
Collectively, these sites performed approximately 195,000 influenza tests over the past year, providing useful context for respiratory testing volumes within these care settings. Their adoption of FebriDx® reinforces growing confidence in rapid diagnostics as an important component of respiratory infection management and a valuable tool in optimizing clinical and operational efficiency across outpatient settings.
As respiratory testing remains inherently seasonal, current efforts are focused on supporting newly onboarded sites through evaluation, implementation, and early use of FebriDx® ahead of the upcoming respiratory season later this year. This includes integrating the test into clinical workflows, establishing ordering patterns, and enabling claims submission to third-party payers—key steps in demonstrating clinical utility, operational efficiency, and the underlying economic value proposition in real-world settings.
The expansion reflects a broader shift toward equipping clinicians with rapid, evidence-based information during the initial patient visit—supporting more confident treatment decisions, reducing diagnostic uncertainty, and reinforcing antimicrobial stewardship efforts. It also enhances patient engagement by enabling more informed discussions around care pathways.
Recent additions, including WellStreet Urgent Care, further highlight the accelerating momentum behind rapid diagnostic solutions that integrate seamlessly into outpatient workflows and support frontline providers.
Collectively, these sites performed approximately 195,000 influenza tests over the past year, providing useful context for respiratory testing volumes within these care settings. Their adoption of FebriDx® reinforces growing confidence in rapid diagnostics as an important component of respiratory infection management and a valuable tool in optimizing clinical and operational efficiency across outpatient settings.
